Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol - Trial NCT06360419
Access comprehensive clinical trial information for NCT06360419 through Pure Global AI's free database. This Phase 3 trial is sponsored by Axsome Therapeutics, Inc. and is currently Recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Axsome Therapeutics, Inc.
Timeline & Enrollment
Phase 3
Mar 18, 2024
Dec 01, 2025
Primary Outcome
Montgomery-Åsberg Depression Rating Scale (MADRS),Incidence of treatment-emergent adverse events
Summary
PARADIGM (Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol)
 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the
 safety and efficacy of solriamfetol for the treatment of major depressive disorder (MDD) in
 adults.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06360419
Non-Device Trial